Structural variability of the carboxy-terminus of Epstein-Barr virus encoded latent membrane protein 1 gene in Hodgkin's lymphomas

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1730-1722

  Guiretti, Deisy M ^a   Chabay, Paola A ^b   Valva, Pamela ^b   Stefanoff, Claudio G ^a   Barros, Mário H M ^a   De Matteo, Elena ^b   Renault, Ilana Zalcberg ^a   Preciado, Maria Victoria ^b   Hassan, Rocio ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

30 bp deletion; EBV; Genetic variability; LMP1

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; LATENT MEMBRANE PROTEIN 1; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARGENTINA; ARTICLE; BRAZIL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; EPSTEIN BARR VIRUS; FEMALE; GENE INSERTION; GENE MUTATION; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LMP1 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; AMINO ACID SEQUENCE; CHEMISTRY; CLASSIFICATION; DNA SEQUENCE; GENE DELETION; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; PATHOGENICITY; VIROLOGY;

HUMAN HERPESVIRUS 4;

AMINO ACID SEQUENCE; ARGENTINA; BRAZIL; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; VARIATION (GENETICS); VIRAL MATRIX PROTEINS;

EID: 34748905598     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21020     Document Type: Article

References (33)

1. Aguilera A. 2002. The connection between transcription and genomic instability. EMBO J 21:195-201.
2. Berger C, Brousset P, McQuain C, Knecht H. 1997. Deletion variants within the NF-kB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations. Leuk Lymphoma 26:239-250.
3. Berger C, van Baarle D, Kersten MJ, Klein MR, Al-Homsi AS, Dunn B, McQuain C, van Oers R, Knecht H. 1999. Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: Reliable markers for individual strain identification. J Infect Dis 179:240-244.
4. Chabay P, De Matteo E, Merediz A, Preciado MV. 2004. High frequency of Epstein Barr virus latent membrane protein-1 30 bp deletion in a series of pediatric malignancies in Argentina. Arch Virol 149:1515-1526.
5. Chen WG, Chen YY, Bacchi MM, Bacchi CE, Alvarenga M, Weiss LM. 1996. Genotyping of Epstein-Barr virus in Brazilian Burkitt's lymphoma and reactive lymphoid tissue. Type A with a high prevalence of deletions within the latent membrane protein gene. Am J Pathol 148:17-23.
6. Chen H, Lee JM, Zong Y, Borowitz M, Ng MH, Ambinder RF, Hayward SD. 2001. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75:2929-2937.
7. Correa M, Fellner D, Alonio L, Durand K, Teyssie A, Picconi MA. 2004. Epstein-Barr virus (EBV) in healthy carriers: Distribution of genotypes and 30 bp deletion in latent membrane protein-1 (LMP-1) oncogene. J Med Virol 73:583-588.
8. Dirnhofer S, Angeles-Angeles A, Ortiz-Hidalgo C, Reyes E, Gredler E, Krugmann J, Fend F, Quintanilla-Martinez L. 1999. High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue. Hum Pathol 30:781-787.
9. Dolcetti R, Zancai P, De Re V, Gloghini A, Bigoni B, Pivetta B, De Vita S, Carbone A, Boiocchi M. 1997. Epstein-Barr virus strains with latent membrane protein-1 deletions: Prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 89:1723-1731.
10. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. 1999. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261:79-95.
11. Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, Rowe M. 2001. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol 75:9129-9141.
12. Goormachtigh G, Ouk TS, Mougel A, Tranchand-Bunel D, Masy E, Le Clorennec C, Feuillard J, Bornkamm GW, Auriault C, Manet E, Fafeur V, Adriaenssens E, Coll J. 2006. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J Virol 80:7382-7393.
13. Guidoboni M, Ponzoni M, Caggiari L, Lettini AA, Vago L, De Re V, Gloghini A, Zancai P, Carbone A, Boiocchi M, Dolcetti R. 2005. Latent membrane protein 1 deletion mutants accumulate in Reed-Sternberg cells of Human immunodeficiency virus-related Hodgkin's lymphoma. J Virol 79:2643-2649.
14. Hassan R, White LR, Stefanoff CG, de Oliveira DE, Felisbino FE, Klumb CE, Bacchi CE, Seuanez HN, Zalcberg IR. 2006. Epstein-Barr Virus (EBV) detection and typing by PCR: A contribution to diagnostic screening of EBV-positive Burkitt's lymphoma. Diagn Pathol 1:17.
15. Hayashi K, Chen WG, Chen YY, Bacchi MM, Bacchi CE, Alvarenga M, Abreu ES, Chang KL, Weiss LM. 1997. Deletion of Epstein-Barr virus latent membrane protein 1 gene in United States and Brazilian Hodgkin's disease and reactive lymphoid tissue: High frequency of a 30-bp deletion. Hum Pathol 28:1408-1414.
16. International Agency for Research on Cancer. 1997. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 70. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon: International Agency for Research on Cancer//World Health Organization, pp 47-373.
17. Jaffe ES, Harris N, Stein H, Vardiman JW, editors. 2001. World Health Organization classification of tumors, pathology and genetics of haemopoietic and lymphoid tissues. Lyon: IARC Press. 244 p.
18. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. 1996. Hodgkin and Reed/Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184:1495-1505.
19. Khanim F, Yao QY, Niedobitek G, Sihota S, Rickinson AB, Young LS. 1996. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88:3491-3501.
20. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942.
21. Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P. 2001. The role of Epstein-Barr virus in neoplastic transformation. Oncology 60:289-302.
22. Mainou BA, Raab-Traub N. 2006. LMP1 strain variants: Biological and molecular properties. J Virol 80:6458-6468.
23. Miller WE, Edwards RH, Walling DM, Raab-Traub N. 1994. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 75:272940.
24. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R. 2001. Hypermutation of multiple protooncogenes in B-cell diffuse large-cell lymphomas. Nature 412:341-346.
25. Preciado MV, De Matteo E, Diez B, Menarguez J, Grinstein S. 1995. Presence of Epstein-Barr virus and strain type assignment in Argentine childhood Hodgkin's disease. Blood 86:3922-3929.
26. Rickinson AB, Kieff EN. 2001. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott-Raven. pp 2575-2627.
27. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning, a laboratory manual, 2nd edition. pp 9.14-9.19.
28. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084-4092.
29. Sandvej K, Peh SC, Andresen BS, Pallesen G. 1994. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84: 4053-4060.
30. Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RL, Andresen BS, Gregersen N, Hamilton-Dutoit S. 1997. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: Identification of four variants among wild-type EBV isolates. Blood 90:323-330.
31. Sandvej K, Andresen BS, Zhou XG, Gregersen N, Hamilton-Dutoit S. 2000. Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: Selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site. Mol Pathol 53:280-288.
32. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, Webster-Cyriaque J. 1999. The molecular epidemiology and evolution of Epstein-Barr virus: Sequence variation and genetic recombination in the latent membrane protein-1 gene. J Infect Dis 179:763-774.
33. Zhou XG, Sandvej K, Li PJ, Ji XL, Yan QH, Zhang XP, Da JP, Hamilton-Dutoit SJ. 2001. Epstein-Barr virus gene polymorphisms in Chinese Hodgkin's disease cases and healthy donors: Identification of three distinct virus variants. J Gen Virol 82:1157-1167.